1469 related articles for article (PubMed ID: 16760442)
41. Cytogenetics as an aid in the diagnosis of lymphomas.
Glassman AB; Hopwood V; Hayes KJ
Ann Clin Lab Sci; 2000 Jan; 30(1):72-4. PubMed ID: 10678586
[TBL] [Abstract][Full Text] [Related]
42. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
43. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
Müller JR; Janz S; Potter M
Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
[TBL] [Abstract][Full Text] [Related]
44. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas.
Piccaluga PP; Califano A; Klein U; Agostinelli C; Bellosillo B; Gimeno E; Serrano S; Solè F; Zang Y; Falini B; Zinzani PL; Pileri SA
Haematologica; 2008 Jul; 93(7):1033-8. PubMed ID: 18492688
[TBL] [Abstract][Full Text] [Related]
45. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.
Bertrand P; Bastard C; Maingonnat C; Jardin F; Maisonneuve C; Courel MN; Ruminy P; Picquenot JM; Tilly H
Leukemia; 2007 Mar; 21(3):515-23. PubMed ID: 17230227
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
47. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
48. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
49. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ
Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438
[TBL] [Abstract][Full Text] [Related]
50. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
52. Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
Ferry JA
Oncologist; 2006 Apr; 11(4):375-83. PubMed ID: 16614233
[TBL] [Abstract][Full Text] [Related]
53. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
[TBL] [Abstract][Full Text] [Related]
54. t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia.
Liu D; Shimonov J; Primanneni S; Lai Y; Ahmed T; Seiter K
Mol Cancer; 2007 Jun; 6():35. PubMed ID: 17547754
[TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas.
Syrjänen S; Kallio P; Sainio P; Fuju C; Syrjänen K
Scand J Dent Res; 1992 Jun; 100(3):176-80. PubMed ID: 1321486
[TBL] [Abstract][Full Text] [Related]
56. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
57. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
[TBL] [Abstract][Full Text] [Related]
58. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene.
Akasaka T; Akasaka H; Ueda C; Yonetani N; Maesako Y; Shimizu A; Yamabe H; Fukuhara S; Uchiyama T; Ohno H
J Clin Oncol; 2000 Feb; 18(3):510-18. PubMed ID: 10653866
[TBL] [Abstract][Full Text] [Related]
59. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression.
Wu D; Wood BL; Dorer R; Fromm JR
Am J Clin Pathol; 2010 Aug; 134(2):258-65. PubMed ID: 20660329
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas.
Tapia G; Lopez R; Muñoz-Mármol AM; Mate JL; Sanz C; Marginet R; Navarro JT; Ribera JM; Ariza A
Histopathology; 2011 Oct; 59(4):672-8. PubMed ID: 22014048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
